1-4 of 4
Emil T. Kuriakose
Close
Sort by
Journal Articles

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study

Reem Karmali, Daniel J. Landsburg, Jason Westin, John P. Leonard, Emil T. Kuriakose, Bradley James Sumrow, Susheela Carroll, Katherine Albert, Lalith Akella, Leo I. Gordon
Journal: Blood
Blood (2022) 140 (Supplement 1): 12125–12126.
https://doi.org/10.1182/blood-2022-165502
Published: 2022
Journal Articles

Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs

Sundar Jagannath, MD, Anuja Roy, PhD, Jonathan K Kish, PhDMPH, Denise Globe, PhD, Orsolya Lunacsek, PhDMBA, Michael T. Eaddy, PharmD, PhD, Emil T Kuriakose, MD, Joanne Willey, RN, David Siegel, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3311.
https://doi.org/10.1182/blood.V126.23.3311.3311
Published: 2015
Journal Articles

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Previously Treated Myeloma

Vincent L Hansen, MD, Morton Coleman, MD, Stephanie Elkins, MD, Jeffrey P. Letzer, Moshe Yair Levy, MD, Lasika Seneviratne, MD, Jessica Rine, Marina White, Emil T Kuriakose, MD
Journal: Blood
Blood (2015) 126 (23): 3027.
https://doi.org/10.1182/blood.V126.23.3027.3027
Published: 2015
Journal Articles

Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma

Hongbo Yang, PhD, Anuja Roy, PhD, Chelsey Yang, Evangeline McDonald, Arun Krishna, PhD, Emil T Kuriakose, MD, Denise Globe, PhD, David Siegel, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2015) 126 (23): 5369.
https://doi.org/10.1182/blood.V126.23.5369.5369
Published: 2015